No Data
No Data
Nikkei Average contribution ranking (pre-market) ~ The Nikkei Average continues to decline, with Tohoku Electric pushing down about 84 yen with only one stock.
As of the closing of 5 days ago, the number of rising stocks in the Nikkei average constituents was 58, the number of falling stocks was 166, and the number of unchanged stocks was 1. The Nikkei average continued to fall. At the end of the morning session, it was 38,527.60 yen (volume approximately 860 million shares) down 309.86 yen (-0.80%) compared to the previous day. On the 4th, the US stock market rose. The Dow average was up 140.26 dollars (+0.36%) to 38,711.29 dollars, and Nasdaq was up 28.38 points (+0.17%) to 16,857.05.
List of cloud breakout stocks (Part 1) [Ichimoku Kinko Hyo Cloud Breakout Stock List]
List of high-flying stocks in the cloud market: Code Name Closing Price Lead Span A Lead Span B Tokyo Prime <2305> Studio Alice 2052 2029.5 2046 <2659> San-Ei 4860 4841.25 4745 <2670> ABC Mart 3090 3039.25 2853 <2899> Nagatanien HD
Nikkei average contribution ratio ranking (closing) - Nikkei average fell for the third day, with First Retail and Laser Tech pushing down about 62 yen in two stocks.
At the end of the day on the 4th, the number of rising stocks in the Nikkei average constituent stocks was 87, the number of falling stocks was 135, and the number of unchanged stocks was 3. On the 3rd, the U.S. stock market was mixed. The Dow Jones Industrial Average closed at 38,571.03, down 115.29 (-0.30%), the Nasdaq rose 93.65 points (+0.56%) to 16,828.67, and the S&P 500 closed at 5,283.40, up 5.89 points (+0.11%). In addition, the May ISM manufacturing index was worse than expected.
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab
Astellas Pharma (TYO:4503) said the US Food and Drug Administration has acknowledged the resubmission of their Biologics License Application (BLA) for zolbetuximab, according to its filing on Friday.
Corbus Outlines Phase 1 Results From ADC Trial for Bladder, Cervical Cancers
Astellas Zolbetuximab Resubmission Accepted by FDA
No Data